Originals
- Gaulhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stättner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B.
Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.
Hepatology 2011; 53(3): 854-864 - William S. Twaddell, Peter C. Wu, Roy J.J. Verhage, Marcus Feith, David H. Ilson, Christoph P. Schuhmacher, James D. Luketich, Björn Brücher, Daniel Vallböhmer, Wayne L. Hofstetter, Mark Jonathan Krasna, Daniela Kandioler, Paul M. Schneider, Bas P.L. Wijnhoven, and Stephen J. Sontag
Barrett’s esophagus: treatments of adenocarcinomas II.
Ann N Y Acad Sci 2011; 1232: 265-91 - Wolf B, Kührer I, Akan B, Teleky B, Kappel S, Schmid R, Wrba F, Mittlböck M, Kandioler D.
PART 1 – p53 adapted preoperative radiotherapy for T2 and T3 rectal cancer. A study of the p53 research group.
Eur Surg 2010; 42(1): 18-23 - Macheiner D, Gauglhofer C, Rodgarkia-Dara C, Grusch M, Brachner A, Bichler C, Kandioler D, Sutterlüty H, Mikulits W, Schulte-Hermann R, Grasl-Kraupp B.
NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.
Cancer Res 2009; 69 (1): 235-242 - Mischek D, Steinborn R, Petznek H, Bichler C, Zatloukal K, Stürzl M, Günzburg WH, Hohenadl C.
Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic stragegies for secondary liver cancers.
J Biomed Biotech 2009; Epub Mar 2009 - Kappel S, Bichler C, Wolf B, Gacic S, Schoppmann SF, Devyatko Y, Prager G, Ba-Ssalamah A, Wrba F, Pluschnig U, Kührer I, Mittlböck M, Hejna M, Zacherl J, Kandioler D, for the Pancho Study Group.
Turning the tables on surgical oncology: the Pancho trial unplugged.
Eur Surg 2008; 40(6): 277-283 - D. Kandioler, on behalf of the pANCHO study directors, investigators and co-workers and the p53 research group.
Personalized medicine – p53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer.
Memo 2008; 1: 137-142 - Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zöchbauer-Müller S, Kührer I, Mittlböck M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Müller MR, Roth E, Klepetko W.
Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
J Thorac Cardiovasc Surg 2008; 135(5): 1036-1041 - Sagmeister S, Drucker C, Losert A, Grusch M, Daryabeigi A, Parzefall W, Rohr-Udilova N, Bichler C, Smedsrød B, Kandioler D, Grünberger T, Wrba F, Schulte-Hermann R, Grasl-Kraupp B.
HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis.
J Hepatol 2008; 49: 955-964 - Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B.
New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis.
Br J Cancer 2008; 99(1): 151-159 - Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Grünberger T, Tamandl D, Filipits M.
Expression of p21(Waf1/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.
Anticancer Res 2007; 27(3B): 1679-1684 - Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC, Zöchbauer-Müller S.
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer.
Breast Cancer Res Treat 2007; 103(3): 283-291 - Kappel S, Kandioler D, Steininger R, Längle F, Wrba F, Ploder M, Berlakovich G, Soliman T, Hetz H, Rockenschaub S, Roth E, Mühlbacher F.
Genetic detection of lymph node micrometastases: a selection criterion for liver transplantation in patients with liver metastases after colorectal cancer.
Transplantation 2006; 81(1): 64-70 - Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung C-S, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O´Donoghue DP, Agnese V, Cascio S, Di Fede G, Chieco-Bianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lothe RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capella GM, Moreno V, Peinado MA, Lönnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh L-L, Tang R, Smith DR, Allen-Mersh TG, Khan Z, Royds J, Shorthouse AJ, Silverman ML, Kato S, Ishioka C; TP53-CRC Collaborative Group
Functional categories of TP53 mutation in colorectal cancer: results of an international collaborative study.
Ann Oncol 2006; 17: 842-847 - Macheiner D, Heller G, Kappel S, Bichler C, Stättner S, Ziegler B, Kandioler D, Wrba F, Schulte-Hermann R, Zöchbauer-Müller S, Grasl-Kraupp B.
NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma.
J Hepatol 2006; 45:81-89 - Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N., for the TP53-CRC Collaborative Study Group.
The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
J Clin Oncol 2005; 23(30): 7518-7528 - Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R.
High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS.
Eur J Surg Oncol 2004; 30: 243-247 - Puhalla H, Kandioler D, Ludwig C, Filipits M, Wrba F, Laengle F, Jakesz R, Gruenberger T.
p53 Analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry.
Anticancer Research 2004; 24: 1201-1206 - Schausberger E, Hufnagl K, Parzefall W, Gerner C, Kandioler- Eckersberger D, Wrba F Klimpfinger M, Schulte-Hermann R, Grasl-Kraupp B.
Inherent growth advantage of (pre)malignant hepatocytes associated with nuclear translocation of pro-transforming growth factor alpha.
Br J Cancer 2004; 91: 1955-1963 - Taucher S, Rudas M, Mader R, Gnant M, Dubsky P, Roka S, Bachleitner T, Kandioler D, Steger G, Mittlböck M, Jakesz R.
Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer.
WiKliWo 2004; 116: 26-31 - Raidl M, Pirker Ch, Schulte-Hermann R, Aubele M, Kandioler-Eckersberger D, Wrba F, Micksche M, Berger W, Grasl-Kraupp B.
Multiple chromosomal abnormalities in human liver (pre)neoplasia.
J Hepatol 2004; 40: 660-668 - Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner Th, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.
Do we need Her-2/neu testing for all patients with primary breast carcinoma?
Cancer 2003; 98: 2547-2553 - Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner Th, Fitzal F, Kandioler D, Wenzel C, Steger GG, Mittlböck M, Jakesz R.
Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of Her-2/neu in patients with breast cancer.
Breast Cancer Res Treat 2003; 82: 207-213 - Stift A, Prager G, Selzer E, Widder J, Kandioler D, Friedl J, Teleky B, Herbst F, Wrba F, Bergmann M.
The early response of p53-dependent proteins during radiotherapy in human rectal carcinoma and in adjacent normal tissue.
Int J Oncology 2003; 23: 1269-1275 - Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittelböck M, Jakesz R.
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.
Endocrine Relat Canc 2003; 10;91.98 - Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R.
Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.
Cell Death Differ 2003; 10: 356-364Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, Sporn E, Jakesz R.
Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen.
Clin Canc Res 2002;8:3427-32 - Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, Agstner I, Seifert M, Sevelda P, Jakesz R.
Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer.
Clin Breast Cancer 2002; 3, 65-72 - Raidl M, Berger W, Schulte-Hermann R, Kandioler-Eckersberger D, Kappel S, Wrba F, Micksche M, Grasl-Kraupp B.
Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis.
Am J Physiol Gastrointest Liver Physiol 2002; 283: G1117-G1124 - Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kührer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Pötter R, Jakesz R, Teleky B, Herbst F.
TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short- term radiotherapy in rectal cancer.
Ann Surg 2002; 235(4): 493-498 - Kandioler-Eckersberger D, Niederle B, Herbst F, Wenzl E.
A magnetic probe to retrieve broken metallic parts of instruments during laparoscopic procedures.
Surg Endosc 2002; 16: 208-209 - Brodowicz T, Kandioler D, Tomek S, Ludwig C, Rudas M, Koestler W, Hejna M, Budinsky A, Krainer M, Wiltschke C, Zielinski CC.
Anti Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independentely from p53 status.
Br J Cancer 2001; 85(11):1764-1770 - Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R – for the Austrian Breast and Colorectal Cancer Study Group
Evaluation of the United States Food and Drug administration –approved scoring and test system of HER-2 protein expression in breast cancer.
Clin Cancer Res 2001; 7: 1669-1675 - Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R.
Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer.
Breast Cancer Res Treat 2001; 67: 1-8 - Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J, Rogy MA.
Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development.
Carcinogenesis 2001; 22(4): 665-671 - Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R.
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Clinical Cancer Research 2000; 6(1): 50-56 - Kandioler-Eckersberger D, Kappel S, Ludwig C, Janschek E, Mannhalter Ch, Eckersberger F.
P53 – vom prognostischen zum prädiktiven Marker.
Acta Chir Austr 2000 ; 32(2): 68-72 - Oehler R, Weingartmann G, Manhart N, Salzer U, Meissner M, Schlegel W, Spittler A, Bergmann M, Kandioler D, Oismüller C, Struse HM, Roth E.
Polytrauma induces increased expression of pyruvate kinase in neutrophils.
Blood 2000;95:1086-1092 - Gebhard B, Gnant M, Schütz G, Roka S, Weigl G, Kandioler D, Taucher S, Grünberger T, Roth E, Jakesz R, Spittler A.
Different Transendothelial Migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast.
Anticancer Research 2000; 20: 4599-4604
Books
- ACO-ASSO Manual der Chirurgischen Krebstherapie. Verlag Krause & Pachernegg GmbH
Herausgeberin : D Kandioler
ISBN 978-3-901299-60-5
Book chapter
- „Designing p53 trials: a surgical oncologists view“; D. Kandioler, S. Kappel, B. Wolf
Springer Verlag - “Sekundäre Neoplasien” B. Rau, D. Kandioler und G. Stamatis. Wiener klinisches Magazin Springer Verlag (2011)
- Lungenmetastasen. B. Rau, D. Kandioler, G. Stamatis In Chirurgische Onkologie/ Strategien und Standards für die Praxis. Hrsg M. Gnant, P.M. Schlag
Springer Wien New York 2008 ISBN 978-3-211-48612-2 - Operative Verfahren bei Präkanzerosen und in situ KarzinomS.F. Schoppmann, D. Kandioler und R. Horvat. In Mammakarzinom/ Operative Behandlungskonzepte
Hrsg Jakesz, Frey
Springer Buch 2007 ISBN 978-3-211-29683-7 - Die Mastektomie – Indikationen und operative Technik aus heutiger Sicht. P. Dubsky und D. Kandioler. In Mammakarzinom/ Operative Behandlungskonzepte
Hrsg Jakesz, Frey
Springer Buch 2007 ISBN 978-3-211-29683-7 - P53 as a Prognostic and Predictive Indicator. Daniela Kandioler, Raimund Jakesz.
In Biomarkers in breast cancer
Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect
Hrsg Gasparini & Hayes
Humana Press 2006 ISBN 1-58829-227-4 - P53 from benchwork to clinical application. Kandioler D
In Forschung ohne Tierversuche
Hrsg Schöffl H, Spielmann H, Tritthart HA.
Springer-Verlag Wien New York 2000 ISBN 3-211-83046-4